Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

MIST

Milestone Pharmaceuticals Inc

Apr 18 • 04:00PM ET

1.63

Dollar change -0.12
Percentage change -6.86	%

Healthcare • Biotechnology • Canada • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: GWX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.48	Insider Own	3.20%	Shs Outstand	53.15M	Perf Week	-3.83%
Market Cap	86.63M	Forward P/E	-	EPS next Y	-1.54	Insider Trans	0.00%	Shs Float	51.45M	Perf Month	12.41%
Income	-59.69M	PEG	-	EPS next Q	-0.26	Inst Own	31.52%	Short Float	1.09%	Perf Quarter	9.40%
Sales	1.00M	P/S	86.63	EPS this Y	17.27%	Inst Trans	4.39%	Short Ratio	1.69	Perf Half Y	-43.60%
Book/sh	0.50	P/B	3.25	EPS next Y	-34.35%	ROA	-79.73%	Short Interest	0.56M	Perf Year	-55.95%
Cash/sh	1.24	P/C	1.31	EPS next 5Y	-	ROE	-143.61%	52W Range	1.33 - 4.49	Perf YTD	-2.40%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-7.22%	ROI	-87.77%	52W High	-63.70%	Beta	1.75
Dividend TTM	-	Quick Ratio	10.11	Sales past 5Y	-29.33%	Gross Margin	40.20%	52W Low	22.56%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	10.11	EPS Y/Y TTM	-7.56%	Oper. Margin	-6141.00%	RSI (14)	44.42	Volatility	8.36% 7.87%
Employees	47	Debt/Eq	3.09	Sales Y/Y TTM	-80.00%	Profit Margin	-5968.50%	Recom	1.50	Target Price	10.50
Option/Short	Yes / Yes	LT Debt/Eq	3.05	EPS Q/Q	-31.98%	Payout	-	Rel Volume	0.63	Prev Close	1.75
Sales Surprise	-	EPS Surprise	-2.40%	Sales Q/Q	-100.00%	Earnings	Mar 21 BMO	Avg Volume	331.14K	Price	1.63
SMA20	-6.11%	SMA50	-1.69%	SMA200	-33.29%	Trades		Volume	208,611	Change	-6.86%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-20-23	Downgrade	Jefferies	Buy → Hold	$8 → $4
Apr-22-22	Upgrade	Piper Sandler	Neutral → Overweight	$8 → $10
Mar-05-21	Initiated	H.C. Wainwright	Buy	$20
Jul-29-20	Upgrade	Oppenheimer	Perform → Outperform	$18
Jul-24-20	Upgrade	Jefferies	Hold → Buy
Mar-25-20	Downgrade	Jefferies	Buy → Hold	$28 → $3
Mar-24-20	Downgrade	Piper Sandler	Overweight → Neutral	$26.50 → $3
Mar-24-20	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-19	Initiated	Oppenheimer	Outperform	$32
Jun-03-19	Initiated	Piper Jaffray	Overweight	$26.50
Jun-03-19	Initiated	Jefferies	Buy	$28
Jun-03-19	Initiated	Cowen	Outperform	$32

Show Previous Ratings

Apr-17-24 08:00AM	Milestone Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium (GlobeNewswire)
Apr-08-24 11:36AM	Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting (GlobeNewswire)
Apr-03-24 08:00AM	Milestone Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference (GlobeNewswire)
Apr-01-24 08:00AM	Milestone Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences (GlobeNewswire)
Mar-28-24 07:00AM	Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia (GlobeNewswire)
01:53PM	Loading…
Mar-21-24 01:53PM	MIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace)
07:14AM	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update (GlobeNewswire)
Feb-29-24 04:01PM	Milestone Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference (GlobeNewswire) -21.13%
07:00AM	Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants (GlobeNewswire)
Feb-28-24 04:37PM	Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants (GlobeNewswire)
Feb-26-24 07:00AM	Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT (GlobeNewswire) +24.12%
Jan-18-24 01:23PM	Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations: Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire)
Jan-16-24 09:35AM	Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround (Zacks)
Dec-27-23 11:11AM	Milestone Pharma (MIST) Down on Regulatory Update for Etripamil (Zacks) -5.53%
Dec-26-23 10:55AM	Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire) -30.90%
07:00AM	Loading…
07:00AM	Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT (GlobeNewswire)
Nov-21-23 07:00AM	Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference (PR Newswire) +13.16%
Nov-13-23 07:02AM	Milestone Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) -19.59%
06:57AM	Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates (PR Newswire)
Nov-11-23 10:00AM	Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023 (PR Newswire)
Nov-07-23 07:00AM	Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR (PR Newswire)
Oct-24-23 07:00AM	Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil (PR Newswire)
Oct-06-23 07:00AM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-27-23 07:00AM	Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023 (PR Newswire)
Sep-05-23 07:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-10-23 07:56AM	Milestone Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance) +5.77%
07:35AM	Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update (PR Newswire)
Aug-08-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More) (TipRanks) +17.63%
Jun-20-23 07:00AM	Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet (PR Newswire)
Jun-10-23 09:40AM	Individual investors account for 48% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 38% (Simply Wall St.)
07:00AM	Loading…
Jun-01-23 07:00AM	Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference (PR Newswire) -6.09%
May-22-23 07:00AM	Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate (PR Newswire)
May-11-23 07:31AM	Milestone Pharmaceuticals: Q1 Earnings Snapshot (AP Finance) +8.97%
07:16AM	Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update (PR Newswire)
May-08-23 07:00AM	Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate (PR Newswire) +9.19%
May-01-23 06:02AM	Lorenz Muller Is The Chief Commercial Officer of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) And They Just Picked Up 23% More Shares (Simply Wall St.)
Apr-21-23 09:23AM	Milestone Pharmaceuticals' (NASDAQ:MIST) investors will be pleased with their decent 75% return over the last three years (Simply Wall St.)
Apr-12-23 07:00AM	Milestone Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-31-23 10:39AM	Despite recent gains, Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insiders are still down US$91k after purchasing last year (Simply Wall St.)
Mar-29-23 09:17AM	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update (PR Newswire)
Mar-28-23 07:00AM	Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT (PR Newswire) +10.83%
Mar-06-23 07:00AM	Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia (PR Newswire) +12.23%
Feb-28-23 07:00AM	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences (PR Newswire)
Jan-16-23 12:00PM	Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why (Zacks)
Jan-01-23 08:33AM	Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is definitely on the radar of institutional investors who own 33% of the company (Simply Wall St.)
Dec-13-22 09:35AM	Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks (Zacks)
Dec-02-22 02:11PM	Will Milestone Pharmaceuticals (NASDAQ:MIST) Spend Its Cash Wisely? (Simply Wall St.)
Nov-29-22 07:00AM	Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT (PR Newswire)
Nov-22-22 07:00AM	Milestone Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference (PR Newswire)
Nov-12-22 07:47AM	Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have unfortunately lost 74% over the last three years (Simply Wall St.)
Nov-10-22 07:21AM	Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update (PR Newswire) +9.54%
Nov-07-22 12:13PM	Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022 (PR Newswire) -10.32%
Oct-25-22 07:00AM	Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022 (PR Newswire) +8.28%
Oct-22-22 08:21AM	Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) recent US$101m market cap decline means a loss of US$6.2k for insiders who bought this year (Simply Wall St.)
08:05AM	Independent Non-Executive Director Michael Tomsicek Just Bought A Handful Of Shares In Milestone Pharmaceuticals Inc. (NASDAQ:MIST) (Simply Wall St.)
Oct-20-22 09:35AM	Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 42.9% in 4 Weeks (Zacks) +5.44%
Oct-18-22 06:30PM	Milestone's (MIST) Tachycardia Study Data Fail to Impress Investors (Zacks) -9.92%
Oct-17-22 09:14AM	Milestone's stock jumps 25% on positive data for tachycardia treatment (MarketWatch) -21.67%
09:12AM	Milestone Pharma Stock Surges After Successful Trial For Abnormal Heart Rhythm Candidate (Benzinga)
06:00AM	Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia (PR Newswire)
Sep-11-22 03:13PM	Oppenheimer Says Biotech Stocks Look a Bit Brighter Right Now; Here Are 2 Names to Consider (TipRanks)
Sep-06-22 07:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Aug-10-22 04:15PM	Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate Update (PR Newswire)
Jul-24-22 10:28AM	What Type Of Shareholders Own The Most Number of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares? (Simply Wall St.)
Jun-02-22 07:00AM	Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference (PR Newswire)
May-27-22 05:03PM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +6.33%
May-23-22 06:23AM	We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth (Simply Wall St.)
May-17-22 07:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference (PR Newswire)
May-12-22 07:15AM	Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update (PR Newswire) -7.40%
Apr-30-22 09:00AM	Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT (PR Newswire)
Apr-15-22 04:41PM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
10:20AM	Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have made a respectable return of 36% over the past year (Simply Wall St.)
Apr-14-22 07:00AM	Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT (PR Newswire)
Mar-24-22 07:20AM	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical and Corporate Update (PR Newswire) +9.28%
Mar-01-22 07:00AM	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences (PR Newswire)
Feb-16-22 07:00AM	Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer (PR Newswire) -5.41%
Feb-14-22 01:03PM	Could The Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Jan-04-22 07:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (PR Newswire)
Dec-14-21 07:56AM	Milestone Pharmaceuticals (NASDAQ:MIST) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Nov-15-21 07:00AM	Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT (PR Newswire) +13.93%
Nov-12-21 07:20AM	Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update (PR Newswire) +8.93%
Nov-11-21 07:00AM	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences (PR Newswire)
Oct-15-21 09:31AM	Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have unfortunately lost 18% over the last year (Simply Wall St.)
Sep-22-21 07:00AM	Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference (PR Newswire)
Sep-07-21 07:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire) -5.99%
Aug-16-21 10:58AM	What Kind Of Shareholders Own Milestone Pharmaceuticals Inc. (NASDAQ:MIST)? (Simply Wall St.)
Aug-11-21 04:18PM	Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update (PR Newswire)
Aug-03-21 09:01AM	10 Stocks to Buy According to Neil Shahrestanis Ikarian Capital (Insider Monkey) -6.56%
May-26-21 07:00AM	Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference (PR Newswire)
May-17-21 01:22PM	Milestone Pharma-Ji Xing Pharma Ink $127M Etripamil Development Agreement For China (Benzinga)
07:02AM	Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21 (PR Newswire)
07:01AM	Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update (PR Newswire)

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MIST

Milestone Pharmaceuticals Inc

Upgrade your FINVIZ experience